Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them - 2The Best Internet based Courses for Expertise Improvement
- 3FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- 4Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- 5Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- Allow Innovative Progressions To have a Tremendous Effect
- Investigating the World's Chief Authentic Urban communities to Visit
- Find Serenity: 10 Stunning Setting up camp Areas
- 'Sex and the City' star Kim Cattrall marries longtime partner Russell Thomas in intimate London wedding
- Understanding Preschool Projects: An Extensive Aide
- Key Training: Picking a Significant for Monetary Achievement
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- Travels to Dream Objections in Europe
